Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02716103 · ClinicalTrials.gov registry record
Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis
A clinical trial, sponsored by Boston Medical Center.
- Completed
- Registry status
- 45
- Enrollment target
NCT02716103: Completed study, sponsored by Boston Medical Center.
NCT02716103 is a clinical trial that has completed, run by Boston Medical Center. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02716103 has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
In this study, the investigators seek to evaluate bone marrow and blood samples and treatment responses to see if Minimal Residual Disease (MRD) can be used as a predictive method of response to treatment in amyloidosis.
Primary Outcome
Number of samples that have a successful isolation of a plasma cell clone
Interventions
- OTHER blood collection
- OTHER bone marrow collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2016-11-21 |
| Est. Completion | 2020-09-04 |
What the finished NCT02716103 record still lists
NCT02716103 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which blood collection is the first listed.
NCT02716103 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02716103 about?
NCT02716103 is a clinical study titled "Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis". In this study, the investigators seek to evaluate bone marrow and blood samples and treatment responses to see if Minimal Residual Disease (MRD) can be used as a predictive method of response to treatment in amyloidosis.
What is the current status of trial NCT02716103?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2016-11-21. Estimated completion is 2020-09-04.
What interventions are being tested in trial NCT02716103?
The interventions under investigation include: blood collection (OTHER), bone marrow collection (OTHER).
Who is sponsoring clinical trial NCT02716103?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI